Last reviewed · How we verify
NCT05447936
Dose Estimation of Jarlsberg Cheese in Young, Active Norwegian Cross-country Skiers (XCS)
NA trial testing Jarlsberg cheese in Healthy Nutrition in 20 participants. Completed in 8 October 2021.
12 August 2021
Quick facts
| Lead sponsor | Meddoc |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 20 |
| Start date | 11 May 2021 |
| Primary completion | 12 August 2021 |
| Estimated completion | 8 October 2021 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Jarlsberg cheese
Conditions studied
- Healthy Nutrition — all drugs for Healthy Nutrition →
Sponsor
Meddoc — full company profile →
Who can join
Adults 18 to 30, any sex, with Healthy Nutrition. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim was to estimate the daily OED of Jarlsberg cheese related to increased total serum Osteocalcin (tOC) level in young, active female and male Cross-country skiers (XCS). The study population consists of active Cross-country Skiers (XCS) of both genders above 18 years of age. The optimal daily intake of Jarlsberg cheese is assumed to have a dose window of \[20 - 100\] gram/day and a starting dose of 47 gram/day for both female and male. The study was performed equally as an open, two-armed within-patient Response Surface Pathway (RSP) trial with three design level and skewed starting dose. The main response variable will be the change in the tOC level after four weeks from baseline of the given design level. Participants, who fulfil the inclusion criteria, do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. All demographic data, social factors, history of disease and vital signs will be recorded at screening. Blood samples was taken at screening and every four weeks. Muscle strength, Peak VO2 and BMD recorded at screening and at the end of the clinical part week12. Ten female and 10 male XCS divided was be included, perform and completed the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05447936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Jarlsberg cheese
Trials testing the same drug.
- NCT06358443 — The Long-term Effect of Daily Jarlsberg Cheese Intake in Patient With Osteopenia · NA · completed
- NCT06688032 — Efficacy Comparison of Jarlsberg- and Norvegia Cheese on Bone Markers and Bone Mineral Density in Nordic Skiers · NA · completed
- NCT05434806 — Daily Dose Estimation of Jarlsberg Cheese in Healthy Norwegian Elderly Male and Female · NA · completed
- NCT04185454 — Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese · NA · completed
Other recruiting trials for Healthy Nutrition
Currently open trials in the same condition.
- NCT06996418 — Intergenerational Mealtime at a Shared Site: A Small-scale Trial · NA · active not recruiting
- NCT06430138 — Bioavailability and Bioactivity of Orange Polyphenols · NA · recruiting
- NCT06310603 — Determinants and Outcomes of High vs. Low Ultra-processed Feeding · NA · active not recruiting
- NCT05869760 — Baylor Infant and Toddler Biomarker of Nutrition Study · recruiting
- NCT05818384 — Wakaya: Rising Up for Choctaw Youth Health · NA · recruiting
Other Meddoc trials
Trials by the same sponsor.
- NCT06973694 — Validation of Bulbicam Used on Patient Suffering From Diabetes Without Retinopathy · completed
- NCT06358443 — The Long-term Effect of Daily Jarlsberg Cheese Intake in Patient With Osteopenia · NA · completed
- NCT05787808 — Profylactic Treatment for Patients in Risk Osteoporosis · NA · recruiting
- NCT06688032 — Efficacy Comparison of Jarlsberg- and Norvegia Cheese on Bone Markers and Bone Mineral Density in Nordic Skiers · NA · completed
- NCT04186585 — Recommended Dose Estimation of BP-C2 · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05447936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meddoc
- Last refreshed: 7 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05447936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing